Page 1055 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

2 References

bacteremia in cancer patients with granulocytopenia. N Engl J 40. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term
Med. 1987;317(27):1692-1698. survival in refractory acute myeloid leukemia after sequential
26. Feld R, Louie TJ, Mandell L, et al. A multicenter compara- treatment with chemotherapy and reduced-intensity condition-
tive trial of tobramycin and ticarcillin vs moxalactam and ing for allogeneic stem cell transplantation. Blood. August 1,
ticarcillin in febrile neutropenic patients. Arch Intern Med. 2006;108(3):1092-1099.
1985;145(6):1083-1088. 41. Khouri IF, Keating M, Korbling M, et al. Transplant-lite:
27. Viscoli C, Bruzzi P, Castagnola E, et al. Factors associated with induction of graft-versus-malignancy using fludarabine-based
bacteremia in febrile, granulocytopenic cancer patients. Eur J nonablative chemotherapy and allogeneic blood progenitor-cell
Cancer. 1994;30A(4):430-437. transplantation as treatment for lymphoid malignancies. J Clin
Oncol. August 1998;16(8):2817-2824.
28. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in
patients with chemotherapy-induced febrile neutropenia - 42. Storb R. Nonmyeloablative preparative regimens: how rel-
a double-blind, placebo-controlled trial. Ann Intern Med. evant for acute myelogenous leukemia? Leukemia. April
1994;121(7):492-501. 2001;15(4):662-663.
29. Dohner H, Estey EH, Amadori S, et al. Diagnosis and manage- 43. Ballen KK, Colvin G, Porter D, Quesenberry PJ. Low dose total
ment of acute myeloid leukemia in adults: recommendations body irradiation followed by allogeneic lymphocyte infusion for
from an international expert panel, on behalf of the European refractory hematologic malignancy–an updated review. Leuk
LeukemiaNet. Blood. January 21 2010;115(3):453-474. Lymphoma. May 2004;45(5):905-910.
30. Bow EJ, Kilpatrick MG, Scott BA, Clinch JJ, Cheang MS. Acute 44. Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning
myeloid leukemia in Manitoba. The consequences of standard for acute graft-versus-host disease. N Engl J Med. September 29,
“7 + 3” remission-induction therapy followed by high dose 2005;353(13):1321-1331.
cytarabine postremission consolidation for myelosuppression, 45. Shorr AF, Moores LK, Edenfield WJ, Christie RJ, Fitzpatrick
infectious morbidity, and outcome. Cancer. 1994;74(1):52-60. TM. Mechanical ventilation in hematopoietic stem cell trans-
31. Bow EJ, Meddings JB. Intestinal mucosal dysfunction and plantation: can we effectively predict outcomes? Chest. October
infection during remission-induction therapy for acute myeloid 1999;116(4):1012-1018.
leukaemia. Leukemia. 2006;20(12):2087-2092. 46. Flowers C, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis
32. Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus and outpatient management of fever and neutropenia in adults
mitoxantrone versus idarubicin as induction and consolida- treated for malignancy: American Society of Clinical Oncology
tion chemotherapy for adults with acute myeloid leukemia: the clinical practice guideline. J Clin Oncol. 2013;31(6):794-810.
EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 47. Cullen MH, Billingham LJ, Gaunt CH, Steven NM. Rational
November 10, 2009;27(32):5397-5403. selection of patients for antibacterial prophylaxis after chemo-
33. Kurrle E, Dekker AW, Gaus W, et al. Prevention of infection in therapy. J Clin Oncol. 2007;25(30):4821-4828.
acute leukemia: a prospective randomized study on the efficacy 48. Lyman GH, Lyman CH, Agboola O. Risk models for predict-
of two different drug regimens for antimicrobial prophylaxis. ing chemotherapy-induced neutropenia. Oncologist. June-July
Infection. 1986;14(5):226-232. 2005;10(6):427-437.
34. Vriesendorp HM. Aims of conditioning. Exp Hematol. October 49. Hosmer W, Malin J, Wong M. Development and validation of
2003;31(10):844-854. a prediction model for the risk of developing febrile neutrope-
nia in the first cycle of chemotherapy among elderly patients
35. Clift RA, Buckner CD, Appelbaum FR, Sullivan KM, Storb R,
Thomas ED. Long-term follow-Up of a randomized trial of two with breast, lung, colorectal, and prostate cancer. Support Care
irradiation regimens for patients receiving allogeneic marrow Cancer. 2011;19(3):333-341.
transplants during first remission of acute myeloid leukemia. 50. Vandyk AD, Harrison MB, Macartney G, Ross-White A, Stacey
Blood. August 15, 1998;92(4):1455-1456. D. Emergency department visits for symptoms experienced by
36. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of oncology patients: a systematic review. Support Care Cancer.
conditioning regimens: working definitions. Biol Blood Marrow August 2012;20(8):1589-1599.
Transplant. December 2009;15(12):1628-1633. 51. Andre S, Taboulet P, Elie C, et al. Febrile neutropenia in French
37. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell emergency departments: results of a prospective multicentre
transplantation using a reduced-intensity conditioning regimen survey. Crit Care. 2010;14(2):R68.
has the capacity to produce durable remissions and long-term 52. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational
disease-free survival in patients with high-risk acute myeloid Association for Supportive Care in Cancer risk index: A multi-
leukemia and myelodysplasia. J Clin Oncol. December 20, national scoring system for identifying low-risk febrile neutro-
2005;23(36):9387-9393. penic cancer patients. J Clin Oncol. 2000;18(16):3038-3051.
38. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem 53. Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a
cell transplantation and cell therapy as an alternative to conven- prospective study to validate the Multinational Association of
tional bone marrow transplantation with lethal cytoreduction Supportive Care of Cancer (MASCC) risk-index score. Support
for the treatment of malignant and nonmalignant hematologic Care Cancer. 2004;12(8):555-560.
diseases. Blood. February 1, 1998;91(3):756-763. 54. Baskaran ND, Gan GG, Adeeba K. Applying the Multinational
39. Corradini P, Zallio F, Mariotti J, et al. Effect of age and previ- Association for Supportive Care in Cancer risk scoring in pre-
ous autologous transplantation on nonrelapse mortality and dicting outcome of febrile neutropenia patients in a cohort of
survival in patients treated with reduced-intensity conditioning patients. Ann Hematol. July 2008;87(7):563-569.
and allografting for advanced hematologic malignancies. J Clin 55. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension
Oncol. September 20, 2005;23(27):6690-6698. before initiation of effective antimicrobial therapy is the critical

Section05-O-ref.indd 2 1/20/2015 4:51:19 PM